<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">diaendo</journal-id><journal-title-group><journal-title xml:lang="ru">Сахарный диабет</journal-title><trans-title-group xml:lang="en"><trans-title>Diabetes mellitus</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0351</issn><issn pub-type="epub">2072-0378</issn><publisher><publisher-name>Endocrinology research centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/DM10103</article-id><article-id custom-type="elpub" pub-id-type="custom">diaendo-10103</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Клинический случай</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Case report</subject></subj-group></article-categories><title-group><article-title>Сочетание активной стадии нейроостеоартропатии Шарко и диабетической макроангиопатии нижних конечностей</article-title><trans-title-group xml:lang="en"><trans-title>Combination of active stage of diabetic Charcot neuroosteoarthropathy and diabetic lower limb macroangiopathy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8126-8452</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Демина</surname><given-names>Анастасия Геннадьевна</given-names></name><name name-style="western" xml:lang="en"><surname>Demina</surname><given-names>Anastasia G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач-эндокринолог кабинета "Диабетическая стопа" </p></bio><bio xml:lang="en"><p>endocrinologist-podiatrist</p></bio><email xlink:type="simple">ans.dem@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5285-8303</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бреговский</surname><given-names>Вадим Борисович</given-names></name><name name-style="western" xml:lang="en"><surname>Bregovskiy</surname><given-names>Vadim B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, врач-эндокринолог кабинета "Диабетическая стопа" </p></bio><bio xml:lang="en"><p>PhD, endocrinologist-podiatrist</p></bio><email xlink:type="simple">podiatr@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2390-8404</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Карпова</surname><given-names>Ирина Альбертовна</given-names></name><name name-style="western" xml:lang="en"><surname>Karpova</surname><given-names>Irina A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кандидат медицинских наук, заведующая </p></bio><bio xml:lang="en"><p>PhD, Chief of the Saint-Petersburg City Diabetes Centre</p></bio><email xlink:type="simple">iakar@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Санкт-Петербургский территориальный диабетологический центр</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Saint-Petersburg City Diabetes Centre</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>17</day><month>01</month><year>2020</year></pub-date><volume>22</volume><issue>5</issue><fpage>491</fpage><lpage>498</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Демина А.Г., Бреговский В.Б., Карпова И.А., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Демина А.Г., Бреговский В.Б., Карпова И.А.</copyright-holder><copyright-holder xml:lang="en">Demina A.G., Bregovskiy V.B., Karpova I.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.dia-endojournals.ru/jour/article/view/10103">https://www.dia-endojournals.ru/jour/article/view/10103</self-uri><abstract><p>Сочетание диабетической нейроостеоартропатии Шарко и диабетической макроангиопатии является редкой патологией. В работе представлены два клинических случая развития диабетической нейроартропатии Шарко на фоне доказанной макроангиопатии артерий нижних конечностей. Первый случай описывает пациента со стабильной перемежающейся хромотой на стадии 2а, у которого случайно выявлена активная рентгенопозитивная диабетическая нейроостеоартропатия. Второй случай представляет пациента, у которого артропатия Шарко развилась после успешной реваскуляризации. У обоих пациентов артропатия характеризовалась отсутствием гиперемии стопы в ранней стадии, небольшим болевым синдромом и отсутствием большого температурного градиента между пораженной и контралатеральной стопами. Лечение у первого пациента состояло из применения тутора, длительность лечения составила 9 мес. Форма стопы почти не изменилась. У второго пациента иммобилизация выполнена при помощи индивидуальной разгрузочной повязки, и лечение еще не закончено. У обоих больных применение магнитно-резонансной томографии выявило гораздо больший масштаб артропатии в сравнении с рентгенологической картиной. История болезни обоих пациентов подчеркивает необходимость высокой настороженности медперсонала в отношении возможности развития артропатии Шарко даже у больных с макроангиопатией нижних конечностей.</p></abstract><trans-abstract xml:lang="en"><p>Combination of active stage of diabetic Charcot neuroosteoarthropathy and diabetic lower limb macroangiopathy is the rare condition. In the present paper we describe two cases of development of acute Charcot foot in the non-critically ischemic foot. The first case is the patient with previously diagnosed intermitted claudication and the second case is patient who developed the Charcot foot 5 months later after successful endovascular treatment of arterial occlusions of his left lower limb. In both cases the absence of redness in the early stage, the mild-to-moderate pain and mild temperature gradient between affected and non-affected feet were noticed. The clinical course of the Charcot disease in the first patient was favourable. He used walker for 9 months and his foot shape was preserved and deformity was considered as mild. The second patient had more active and profound destructions due to delay of the treatment. He was casted, however his deformity progressed and the treatment continues up to date. In both patients the MRI revealed more affected bones compared with X-ray. These cases emphasize the importance of keeping in mind the Charcot disease even in patients with diabetic peripheral vascular disease.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>клинический случай</kwd><kwd>диабетическая нейроартропатия</kwd><kwd>артропатия Шарко</kwd><kwd>диабетическая ангиопатия</kwd><kwd>сахарный диабет</kwd></kwd-group><kwd-group xml:lang="en"><kwd>case report</kwd><kwd>diabetic neuroosteoarthropathy</kwd><kwd>Charcot foot</kwd><kwd>diabetic angiopathy</kwd><kwd>diabetes mellitus</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Rogers L, Frykberg R, Armstrong D, et al. The Charcot foot in diabetes. Diabetes Care. 2011;34(9):2123−2129. doi: https://doi.org/10.2337/dc11-0844</mixed-citation><mixed-citation xml:lang="en">Rogers L, Frykberg R, Armstrong D, et al. The Charcot foot in diabetes. Diabetes Care. 2011;34(9):2123−2129. doi: https://doi.org/10.2337/dc11-0844</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Wukich DK, Raspovic KM, Suder NC. Prevalence of peripheral arterial disease in patients with diabetic Charcot neuroarthropathy. J Foot Ankle Surg. 2016;55(4):727–731. doi: https://doi.org/10.1053/j.jfas.2016.01.051</mixed-citation><mixed-citation xml:lang="en">Wukich DK, Raspovic KM, Suder NC. Prevalence of peripheral arterial disease in patients with diabetic Charcot neuroarthropathy. J Foot Ankle Surg. 2016;55(4):727–731. doi: https://doi.org/10.1053/j.jfas.2016.01.051</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Jeffcoate W. Vascular calcification and osteolysis in diabetic neuropathy — is RANK-L the missing link? Diabetologia. 2004;47(9):1488–1492. doi: https://doi.org/10.1007/s00125-004-1477-5</mixed-citation><mixed-citation xml:lang="en">Jeffcoate W. Vascular calcification and osteolysis in diabetic neuropathy — is RANK-L the missing link? Diabetologia. 2004;47(9):1488–1492. doi: https://doi.org/10.1007/s00125-004-1477-5</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ярославцева M.В., Ульянова И.Н., Галстян Г.Р. Система остеопротегерин (OPG)-лиганд рецептора-активатора ядерного фактора каппа-В (RANKL) при диабетической нейроостеоартропатии и облитерирующем атеросклерозе артерий нижних конечностей // Сахарный диабет. — 2007. — №2. — С. 24–28. [Yaroslavtceva MV, Ulianova IN, Galstian GR. Sistema osteoprotegerin (OPG)-ligand receptora-activatora yadernogo factora kappa-B (RANKL) pri diabeticheskoy neuroosteoartropatii i obliteriruyuschem aterosklerose arterii nizhnih konechnostei. Diabetes Mellitus. 2007;(2):24−28. (In Russ.)] doi: https://doi.org/10.14341/2072-0351-5792</mixed-citation><mixed-citation xml:lang="en">Ярославцева M.В., Ульянова И.Н., Галстян Г.Р. Система остеопротегерин (OPG)-лиганд рецептора-активатора ядерного фактора каппа-В (RANKL) при диабетической нейроостеоартропатии и облитерирующем атеросклерозе артерий нижних конечностей // Сахарный диабет. — 2007. — №2. — С. 24–28. [Yaroslavtceva MV, Ulianova IN, Galstian GR. Sistema osteoprotegerin (OPG)-ligand receptora-activatora yadernogo factora kappa-B (RANKL) pri diabeticheskoy neuroosteoartropatii i obliteriruyuschem aterosklerose arterii nizhnih konechnostei. Diabetes Mellitus. 2007;(2):24−28. (In Russ.)] doi: https://doi.org/10.14341/2072-0351-5792</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Palena LM, Brocco E, Ninkovic S, et al. Ischemic Charcot foot: different disease with different treatment? J Cardiovasc Surg (Torino). 2013;54(5):561–566.</mixed-citation><mixed-citation xml:lang="en">Palena LM, Brocco E, Ninkovic S, et al. Ischemic Charcot foot: different disease with different treatment? J Cardiovasc Surg (Torino). 2013;54(5):561–566.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Рекомендации ЕОК/ЕОСХ по диагностике и лечению заболеваний периферических артерий 2017 // Российский кардиологический журнал. 2018;23(8) [интернет-ресурс]. [2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for vascular surgery (ESVS). Russian journal of cardiology. 2018;23(8) [online resource]. (In Russ.)] Доступно по: http://www.scardio.ru/content/Guidelines/8_rkj_2018_recomendation_2.pdf. Ссылка активна на 15.07.2019.</mixed-citation><mixed-citation xml:lang="en">Рекомендации ЕОК/ЕОСХ по диагностике и лечению заболеваний периферических артерий 2017 // Российский кардиологический журнал. 2018;23(8) [интернет-ресурс]. [2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for vascular surgery (ESVS). Russian journal of cardiology. 2018;23(8) [online resource]. (In Russ.)] Доступно по: http://www.scardio.ru/content/Guidelines/8_rkj_2018_recomendation_2.pdf. Ссылка активна на 15.07.2019.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Milne T, Rogers J, Kinnear E, et al. Developing an evidence-based clinical pathway for the assessment, diagnosis and management of acute Charcot neuro-arthropathy: a systematic review. J Foot Ankle Res. 2013;6(1):30. doi: https://doi.org/10.1186/1757-1146-6-30</mixed-citation><mixed-citation xml:lang="en">Milne T, Rogers J, Kinnear E, et al. Developing an evidence-based clinical pathway for the assessment, diagnosis and management of acute Charcot neuro-arthropathy: a systematic review. J Foot Ankle Res. 2013;6(1):30. doi: https://doi.org/10.1186/1757-1146-6-30</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Chantelau E, Richter A. The acute diabetic Charcot foot managed on the basis of magnetic resonance imaging — a review of 71 cases. Swiss Med Wkly. 2013;143:w13831. doi: https://doi.org/10.4414/smw.2013.13831</mixed-citation><mixed-citation xml:lang="en">Chantelau E, Richter A. The acute diabetic Charcot foot managed on the basis of magnetic resonance imaging — a review of 71 cases. Swiss Med Wkly. 2013;143:w13831. doi: https://doi.org/10.4414/smw.2013.13831</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
